Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Immunocore Holdings plc (Nasdaq: IMCR) to present at the 42nd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 42^nd Annual J.P. Morgan Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in a presentation at the 42^nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

The presentation is scheduled for Wednesday, January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST).

The presentation will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.

About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT: 
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com

FAQ

What is the company name and ticker symbol for the presenter at the 42nd Annual J.P. Morgan Healthcare Conference?

The company presenting at the conference is Immunocore Holdings plc, and its ticker symbol is IMCR.

What is the focus of Immunocore Holdings plc?

Immunocore Holdings plc is a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases.

When and where will the presentation take place?

The presentation is scheduled for Wednesday, January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST) at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

How can the presentation be accessed?

The presentation will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation will be made available for a limited time after the event.